| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
2 P12A and Type 2 Diabetes in Canadian Oji-Cree1
John P. Robarts Research Institute (R.A.H., H.C., C.M.A.) and Centre for Studies in Family Medicine (S.B.H.), University of Western Ontario, London, Ontario, Canada N6A 5K8; and Samuel Lunenfeld Research Institute and Department of Medicine (B.Z., A.J.G.H.), Mount Sinai Hospital, University of Toronto, Ontario, Canada M5G 1X5
Address correspondence and requests for reprints to: Robert A. Hegele, Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 406-100 Perth Drive, London, Ontario, Canada N6A 5K8. E-mail: robert.hegele{at}rri.on.ca
Among the Oji-Cree of northern Ontario, we previously identified a novel variant in the HNF1A gene, namely G319S, that was strongly associated with type 2 diabetes. However, the majority of subjects with diabetes did not have the HNF1A S319 variant, suggesting that there might be other genetic determinants of diabetes susceptibility. In the course of sequencing candidate genes in diabetic subjects who were homozygous for HNF1A G319/G319, we found that some of them had the PPARG A12 variant. After genotyping PPARG in the entire adult Oji-Cree population, we found that: 1) PPARG A12 was strongly associated with type 2 diabetes in women, but not men; 2) among women, the odds of being affected for carriers of PPARG A12 compared with noncarriers was 2.3 (95% confidence interval, 1.43.8); and 3) among women, affected carriers of PPARG A12 had a significantly earlier age-of-onset and/or age-at-diagnosis compared with noncarriers. When taken together with the previously reported association of diabetes with HNF1A in both men and women, the gender-specific association with PPARG A12 confirms that type 2 diabetes is etiologically complex in the Oji-Cree and that at least two genes are involved in determining susceptibility to the disease in these people.
This article has been cited by other articles:
![]() |
S. Savas, I. W. Taylor, J. L. Wrana, and H. Ozcelik Functional nonsynonymous single nucleotide polymorphisms from the TGF-{beta} protein interaction network Physiol Genomics, April 24, 2007; 29(2): 109 - 117. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tonjes, M. Scholz, M. Loeffler, and M. Stumvoll Association of Pro12Ala Polymorphism in Peroxisome Proliferator-Activated Receptor {gamma} With Pre-Diabetic Phenotypes: Meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care, November 1, 2006; 29(11): 2489 - 2497. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Soriguer, S. Morcillo, F. Cardona, G. Rojo-Martinez, M. de la Cruz Almaraz, M. de la Soledad Ruiz de Adana, G. Olveira, F. Tinahones, and I. Esteva Pro12Ala Polymorphism of the PPARG2 Gene Is Associated with Type 2 Diabetes Mellitus and Peripheral Insulin Sensitivity in a Population with a High Intake of Oleic Acid J. Nutr., September 1, 2006; 136(9): 2325 - 2330. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Pischon, J. K. Pai, J. E. Manson, F. B. Hu, K. M. Rexrode, D. Hunter, and E. B. Rimm Peroxisome Proliferator-Activated Receptor-{gamma}2 P12A Polymorphism and Risk of Coronary Heart Disease in US Men and Women Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1654 - 1658. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Ruiz-Narvaez Is the Ala12 variant of the PPARG gene an "unthrifty allele"? J. Med. Genet., July 1, 2005; 42(7): 547 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Hansen, E.-M. D. Nielsen, J. Ek, G. Andersen, C. Glumer, B. Carstensen, P. Mouritzen, T. Drivsholm, K. Borch-Johnsen, T. Jorgensen, et al. Analysis of Separate and Combined Effects of Common Variation in KCNJ11 and PPARG on Risk of Type 2 Diabetes J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3629 - 3637. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Murtaugh, K.-n. Ma, B. J. Caan, C. Sweeney, R. Wolff, W. S. Samowitz, J. D. Potter, and M. L. Slattery Interactions of Peroxisome Proliferator-Activated Receptor {gamma} and Diet in Etiology of Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1224 - 1229. [Abstract] [Full Text] [PDF] |
||||
![]() |
E J Parra, C J Hoggart, C Bonilla, S Dios, J M Norris, J A Marshall, R F Hamman, R E Ferrell, P M McKeigue, and M D Shriver Relation of type 2 diabetes to individual admixture and candidate gene polymorphisms in the Hispanic American population of San Luis Valley, Colorado J. Med. Genet., November 1, 2004; 41(11): e116 - e116. [Full Text] [PDF] |
||||
![]() |
R. E. Pisabarro, C. Sanguinetti, M. Stoll, and D. Prendez High Incidence of Type 2 Diabetes in Peroxisome Proliferator-Activated Receptor {gamma}2 Pro12Ala Carriers Exposed to a High Chronic Intake of Trans Fatty Acids and Saturated Fatty Acids Diabetes Care, September 1, 2004; 27(9): 2251 - 2252. [Full Text] [PDF] |
||||
![]() |
R. A. Hegele, H. Cao, C. Frankowski, S. T. Mathews, and T. Leff PPARG F388L, a Transactivation-Deficient Mutant, in Familial Partial Lipodystrophy Diabetes, December 1, 2002; 51(12): 3586 - 3590. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. I. Lindi, M. I.J. Uusitupa, J. Lindstrom, A. Louheranta, J. G. Eriksson, T. T. Valle, H. Hamalainen, P. Ilanne-Parikka, S. Keinanen-Kiukaanniemi, M. Laakso, et al. Association of the Pro12Ala Polymorphism in the PPAR-{gamma}2 Gene With 3-Year Incidence of Type 2 Diabetes and Body Weight Change in the Finnish Diabetes Prevention Study Diabetes, August 1, 2002; 51(8): 2581 - 2586. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Eriksson, V. Lindi, M. Uusitupa, T. J. Forsen, M. Laakso, C. Osmond, and D. J.P. Barker The Effects of the Pro12Ala Polymorphism of the Peroxisome Proliferator-Activated Receptor-{gamma}2 Gene on Insulin Sensitivity and Insulin Metabolism Interact With Size at Birth Diabetes, July 1, 2002; 51(7): 2321 - 2324. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mok, H. Cao, B. Zinman, A. J. G. Hanley, S. B. Harris, B. P. Kennedy, and R. A. Hegele A Single Nucleotide Polymorphism in Protein Tyrosine Phosphatase PTP-1B Is Associated with Protection from Diabetes or Impaired Glucose Tolerance in Oji-Cree J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 724 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. van Tilburg, T. W van Haeften, P. Pearson, and C. Wijmenga Defining the genetic contribution of type 2 diabetes mellitus J. Med. Genet., September 1, 2001; 38(9): 569 - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Hegele, S. B. Harris, B. Zinman, A. J.G. Hanley, and H. Cao Absence of Association of Type 2 Diabetes With CAPN10 and PC-1 Polymorphisms in Oji-Cree Diabetes Care, August 1, 2001; 24(8): 1498 - 1499. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |